Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2007.0004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults.
J Clin Med
December 2024
Department of Pharmacy, CHOC Children's Hospital, Orange, CA 92868, USA.
: Cannabinoid Hyperemesis Syndrome (CHS), associated with long-term cannabinoid use, has been increasingly observed in emergency room visits as more states in the U.S. have legislatively permitted medical and recreational marijuana use.
View Article and Find Full Text PDFClinical benefits of adding olanzapine to 5-HT receptor antagonist, NK receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
January 2025
Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara‑Cho, Sakyo-ku, Shogoin, Kyoto, 606‑8507, Japan.
Article Synopsis
- Olanzapine is an atypical antipsychotic that helps prevent nausea and vomiting, particularly after highly emetogenic chemotherapy (HEC), but it can cause side effects like hyperglycemia and drowsiness.
- A systematic review and meta-analysis assessed the effectiveness of olanzapine combined with standard triplet antiemetic therapy compared to triplet therapy alone, focusing on outcomes like nausea control and adverse effects.
- Results showed that adding olanzapine significantly improved nausea and vomiting prevention in both acute and delayed phases with minimal adverse effects, indicating it can be beneficial for patients undergoing HEC.
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Int J Clin Oncol
January 2025
Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45‑1, Nanakuma, Jonan‑Ku, Fukuoka, 814‑0180, Japan.
Article Synopsis
- Research lacks a standardized multi-day antiemetic regimen for chemotherapy, making it difficult to assess efficacy and safety.
- A comprehensive search revealed no direct comparisons between multi-day and single-day antiemetic regimens, with variations in study quality and treatment protocols hindering robust analysis.
- Preliminary findings indicate that three-drug combination therapies, particularly using aprepitant, may outperform two-drug regimens; further research is needed to better define antiemetic approaches for multi-day chemotherapy.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy: a systematic review and meta-analysis of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology.
Int J Clin Oncol
December 2024
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1‑20‑1 Handayama, Chuo-Ku, Hamamatsu, Shizuoka, 431‑3192, Japan.
Article Synopsis
- Palonosetron is a second-generation anti-nausea drug that might be more effective than first-generation medications, and this study explores how dexamethasone (DEX) works with it during chemotherapy.
- Researchers compared the effects of giving DEX for 1 day versus 3 days in preventing nausea and vomiting after moderately emetogenic chemotherapy (MEC), using data from studies published between 1990 and 2020.
- The findings showed that while the 3-day DEX group had a higher rate of no vomiting, there were no major differences in most anti-nausea effects, suggesting that DEX treatment could be shortened to just 1 day when paired with palonosetron.
Efficacy and safety of dexamethasone sparing for the prevention of nausea and vomiting associated with highly emetogenic risk antineoplastic agents: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
November 2024
Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu, Shizuoka, 431-3192, Japan.
Article Synopsis
- - The study focuses on the effectiveness and safety of dexamethasone-sparing antiemetic therapies, particularly neurokinin-1 antagonists (NKRA), for preventing chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC).
- - A systematic review of literature identified and analyzed two studies involving anthracycline-cyclophosphamide and cisplatin-based regimens; while no significant differences in vomiting prevention were found, some outcomes related to nausea showed variability.
- - The review concludes that dexamethasone-sparing antiemetic therapies can be effective in preventing CINV for HEC, particularly in patients receiving anthracycline-cyclophosphamide
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!